Using a panel of 12 patient-derived glioblastoma cell lines, we investigated the chemo- and radio-sensitising effect of gartisertib, a potent and selective inhibitor of ATR [26] that was explored in a phase 1 clinical trial for patients with advanced solid tumours (NCT02278250). Here, ATR is linked to glioblastoma.